Skip to main content

Table 3 Survival data with prospective phase 2 trials and retrospective series

From: Chordoma: a case series and review of the literature

Phase 2 Trials

Retrospective series

Treatment

Lapatinib [12]

Sorafenib [13]

Imatinib [10]

French Sarcoma Group [15]

Imatinib [11]

Pazopanib and sunitinib [16]

Number of cases

18

27

56

80

48

5

PFS (months)

8.2

NR

9

9.4

9.9

14

OS (months)

25

NR*

34.5

52.8

30

-

BORR (%)

0

3.7

2

6

0

20 (one patient)

  1. BORR best objective response rate, NR not reached but > 15 months, OS median overall survival, PFS median progression-free survival, * 12 months OS rate 86.5%
Back to article page

Journal of Medical Case Reports

ISSN: 1752-1947